Document is current

Article History

Accepted: 30 January 2023

First Online: 28 February 2023

Declarations

:

: Open Access funding enabled and organized by Projekt DEAL. This research received no specific funding and no funding was provided for the publication of this article.

: KD has received travel support from Servier, GSK, and BMS. DZ has received travel support from AstraZeneca, Amgen, and BMS, as well as honoraria from AstraZeneca. LW has received honoraria from Roche, Servier, and Amgen. GB has received honoraria from Falk Foundation and Akcea. WGK has received honoraria from BMS. MS has received research grants from Bayer Healthcare and SIRTEX Medical, as well as lecture honoraria from Bayer Healthcare, SIRTEX Medical, Cook, Boston Scientific, LIAM, Siemens, Balt, Astra Zeneca, and Falk. SC has received research grants from Elekta, Viewray, and Brainlab and speaker fees/travel support from Elekta, Viewray, C-RAD, Roche, and Brainlab. JK received honoraria and reimbursement for travel and accommodation for participation in advisory boards and in the speakers’ bureau from AstraZeneca, Novartis, and Roche Pharma. MvB has received research support from and serves on the speakers’ bureau at Gilead, Miltenyi Biotec, MSD Sharpe & Dohme, Roche, Mologen, Novartis, Astellas, and BMS. SB reports personal fees from Celgene/BMS, AstraZeneca, Servier, Janssen-Cilag, and MSD (honoraria for scientific presentations and a paid consultant), as well as research support from Celgene outside the submitted work. VH reports grants, honoraria, and non-financial support from Amgen, Astra-Zeneca, Baxalta, Boehringer-Ingelheim, Celgene/BMS, Halozyme, Lilly, Merck, MSD, Novartis, OncoSil, Pierre-Fabre, Roche, Sanofi, Servier, Shire, Sirtex, Taiho, and Terumo. CBW has received honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, SIRTeX, and Taiho; served on advisory boards for Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire/Baxalta, Rafael Pharmaceuticals, RedHill, and Roche; has received travel support by Bayer, Celgene, Janssen, RedHill, Roche, Servier, and Taiho and research grants (institutional) by Roche. CBW serves as an officer for the European Society of Medical Oncology, Deutsche Krebshilfe, and Arbeitsgemeinschaft internistische Onkologie, and is a member of the European Union Commission expert group: Mission Board for cancer. The remaining authors have no conflicts of interest to declare.

: This retrospective chart review study involving human participants was in accordance with the principles of the Declaration of Helsinki and its later amendments. The study has been approved by the local Ethics Committee of the Ludwig Maximilian University of Munich (project number 21-0869), as has the study of the comparative group (284–10).

: Not applicable.

: Not applicable.

: The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

: Not applicable.

: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by KD, DZ, LR, and CBW. The first draft of the manuscript was written by KD and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript and agree to be accountable for the work.